Developer docs
API playgroundTry for free, no card

Search company profiles

Gilead Sciences Pharmaceuticals Co.

Full company profile

uuid003gg8j

Namestring
Gilead Sciences Pharmaceuticals Co.
Legal namestring
吉利德(上海)医药科技有限公司
Websiteurl
gileadchina.com
Company typeenum
Private
Founded yearint
1987
Short descriptiontext

Gilead Sciences Pharmaceuticals Co. (吉利德(上海)医药科技有限公司) is the China regional subsidiary of NASDAQ-listed Gilead Sciences, Inc., commercializing innovative therapeutics for HIV, viral hepatitis, inflammatory diseases, and oncology to Chinese patients through hospitals, physicians, and specialty pharmacy channels.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersShanghai, China
HQ citystring
Shanghai
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antiviral pharmaceuticals, HIV treatment medicines, viral hepatitis therapies, oncology drug development, clinical research services
Industry2 codes
PRIMARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing32541
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Biopharmaceuticals
Social media profiles1 record
Revenue model1 record
1Pharmaceutical drug sales
TypeOne Time License
Description

Gilead generates revenue through the sale of prescription pharmaceutical products, developing and commercializing innovative medicines for patients with serious diseases.

gileadchina.cn:443
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Gilead Sciences Pharmaceuticals Co. (吉利德(上海)医药科技有限公司) is a biopharmaceutical company that develops, manufactures, and commercializes innovative prescription medicines for serious and life-threatening diseases. Its therapeutic focus centers on virology (HIV/AIDS and viral hepatitis) and oncology, with the company investing in world-class scientific research and simplified treatment regimens to expand patient access in China. The entity operates as the Chinese regional subsidiary of Gilead Sciences, Inc.

Differentiator
Functional benefit
Problem solved
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Peers10 records
TypeBroad incumbent
Description

J&J China operates a large innovative medicine subsidiary with HIV, oncology, and immunology franchises. It is comparable as a multinational pharma China entity with overlapping therapeutic categories, particularly HIV where J&J has historic market presence.

TypeBroad incumbent
Description

Novartis China operates a specialty-focused multinational pharma subsidiary with major oncology and infectious disease franchises. It is comparable as a multinational parent's China entity with overlapping therapeutic emphasis and similar NRDL/pricing exposure.

TypeEmerging player
Description

BeiGene is a China-headquartered oncology biotech with growing global presence, competing with multinational pharma in hematology and solid tumor oncology. It is comparable as a competitor in the China oncology space, particularly relevant given domestic Chinese player dynamics affecting Gilead's subsidiary.

4AstraZeneca (China)
TypeBroad incumbent
Description

AstraZeneca China is one of the largest multinational pharma subsidiaries by China revenue, with a broad oncology and specialty pipeline. It is comparable as a multinational pharma's China commercial vehicle with significant NRDL exposure and specialty drug focus.

5Bristol-Myers Squibb (China)
TypeDirect peer
Description

Bristol-Myers Squibb operates a major China subsidiary focused on oncology, hematology, and immunology. It is directly comparable as a multinational biopharmaceutical subsidiary with a similar therapeutic mix (oncology and specialty) and similar commercial infrastructure in China.

6Roche (China)
TypeBroad incumbent
Description

Roche China is a leading multinational oncology and specialty pharma subsidiary. It is comparable as a U.S./European-headquartered parent's China entity with major emphasis on oncology therapeutics and similar specialty distribution infrastructure.

TypeDirect peer
Description

AbbVie China operates as a specialty-focused multinational subsidiary with strengths in HIV (via its collaboration history) and oncology/hematology. It is comparable given similar therapeutic mix and reliance on parent pipeline for specialty drug launches in China.

TypeDirect peer
Description

GSK China operates as a multinational subsidiary with a strong HIV franchise (via ViiV Healthcare) and infectious disease pipeline. It is directly comparable as a multinational pharma parent with China presence competing in the same HIV and hepatitis therapeutic categories.

9Merck & Co. (MSD China)
TypeDirect peer
Description

MSD China operates one of the largest multinational pharma subsidiaries in China with leadership in oncology (Keytruda) and a growing infectious disease portfolio. It is comparable as a U.S. pharma parent's China entity with overlapping therapeutic emphasis on oncology and specialty therapeutics.

TypeBroad incumbent
Description

Pfizer China is one of the largest multinational pharma operations in China across multiple therapeutic areas including oncology and infectious diseases. It is comparable as a broader incumbent multinational subsidiary with overlapping focus areas but a much wider portfolio.

Market position
Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Gilead Sciences Pharmaceuticals Co.

Biopharmaceuticalsgileadchina.com

Gilead Sciences Pharmaceuticals Co. (吉利德(上海)医药科技有限公司) is the China regional subsidiary of NASDAQ-listed Gilead Sciences, Inc., commercializing innovative therapeutics for HIV, viral hepatitis, inflammatory diseases, and oncology to Chinese patients through hospitals, physicians, and specialty pharmacy channels.

Gilead Sciences Pharmaceuticals Co. firmographics

Firmographics
Name
Gilead Sciences Pharmaceuticals Co.
Legal name
吉利德(上海)医药科技有限公司
Website
https://gileadchina.com
Company type
Private
Founded year
1987
Operating status
Operating
Headcount range
101–250 employees
Short description
Gilead Sciences Pharmaceuticals Co. (吉利德(上海)医药科技有限公司) is the China regional subsidiary of NASDAQ-listed Gilead Sciences, Inc., commercializing innovative therapeutics for HIV, viral hepatitis, inflammatory diseases, and oncology to Chinese patients through hospitals, physicians, and specialty pharmacy channels.
Ownership category
akta.pro rank

Gilead Sciences Pharmaceuticals Co. industry classification

Industry
Product category
Biopharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Antiviral pharmaceuticals
  • HIV treatment medicines
  • Viral hepatitis therapies
  • Oncology drug development
  • Clinical research services

Where Gilead Sciences Pharmaceuticals Co. is headquartered

Location

Headquarters

HQ city
Shanghai
HQ country
China
HQ region
Asia

Offices1 record

Markets served

Gilead Sciences Pharmaceuticals Co. business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

  1. Pharmaceutical drug sales: Gilead generates revenue through the sale of prescription pharmaceutical products, developing and commercializing innovative medicines for patients with serious diseases.

Distribution channels2 records

Marketing channels2 records

Gilead Sciences Pharmaceuticals Co. product offering

Product offering

Core offering

Gilead Sciences Pharmaceuticals Co. (吉利德(上海)医药科技有限公司) is a biopharmaceutical company that develops, manufactures, and commercializes innovative prescription medicines for serious and life-threatening diseases. Its therapeutic focus centers on virology (HIV/AIDS and viral hepatitis) and oncology, with the company investing in world-class scientific research and simplified treatment regimens to expand patient access in China. The entity operates as the Chinese regional subsidiary of Gilead Sciences, Inc.

Differentiator

Problem solved

Functional benefit

Companies that use Gilead Sciences Pharmaceuticals Co.

Customer profile

Segments1 record

Ideal customer profiles1 record

Gilead Sciences Pharmaceuticals Co. technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Gilead Sciences Pharmaceuticals Co. partnerships and signals

Strategic signal

Scale indicators1 record

Gilead Sciences Pharmaceuticals Co. competitors and assessment

Company assessment

Broad incumbents

  • Johnson & Johnson Innovative Medicine (China): J&J China operates a large innovative medicine subsidiary with HIV, oncology, and immunology franchises. It is comparable as a multinational pharma China entity with overlapping therapeutic categories, particularly HIV where J&J has historic market presence.
  • Novartis (China): Novartis China operates a specialty-focused multinational pharma subsidiary with major oncology and infectious disease franchises. It is comparable as a multinational parent's China entity with overlapping therapeutic emphasis and similar NRDL/pricing exposure.
  • AstraZeneca (China): AstraZeneca China is one of the largest multinational pharma subsidiaries by China revenue, with a broad oncology and specialty pipeline. It is comparable as a multinational pharma's China commercial vehicle with significant NRDL exposure and specialty drug focus.
  • Roche (China): Roche China is a leading multinational oncology and specialty pharma subsidiary. It is comparable as a U.S./European-headquartered parent's China entity with major emphasis on oncology therapeutics and similar specialty distribution infrastructure.
  • Pfizer (China): Pfizer China is one of the largest multinational pharma operations in China across multiple therapeutic areas including oncology and infectious diseases. It is comparable as a broader incumbent multinational subsidiary with overlapping focus areas but a much wider portfolio.

Emerging players

  • BeiGene: BeiGene is a China-headquartered oncology biotech with growing global presence, competing with multinational pharma in hematology and solid tumor oncology. It is comparable as a competitor in the China oncology space, particularly relevant given domestic Chinese player dynamics affecting Gilead's subsidiary.

Direct peers

  • Bristol-Myers Squibb (China): Bristol-Myers Squibb operates a major China subsidiary focused on oncology, hematology, and immunology. It is directly comparable as a multinational biopharmaceutical subsidiary with a similar therapeutic mix (oncology and specialty) and similar commercial infrastructure in China.
  • AbbVie (China): AbbVie China operates as a specialty-focused multinational subsidiary with strengths in HIV (via its collaboration history) and oncology/hematology. It is comparable given similar therapeutic mix and reliance on parent pipeline for specialty drug launches in China.
  • GSK (China): GSK China operates as a multinational subsidiary with a strong HIV franchise (via ViiV Healthcare) and infectious disease pipeline. It is directly comparable as a multinational pharma parent with China presence competing in the same HIV and hepatitis therapeutic categories.
  • Merck & Co. (MSD China): MSD China operates one of the largest multinational pharma subsidiaries in China with leadership in oncology (Keytruda) and a growing infectious disease portfolio. It is comparable as a U.S. pharma parent's China entity with overlapping therapeutic emphasis on oncology and specialty therapeutics.

Market position

Customer concentration

Gilead Sciences Pharmaceuticals Co. social profiles

Digital presence

Gilead Sciences Pharmaceuticals Co. financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Gilead Sciences Pharmaceuticals Co. leadership team

Management profile

Number of profiles

Gilead Sciences Pharmaceuticals Co. funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Gilead Sciences Pharmaceuticals Co. M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gilead Sciences Pharmaceuticals Co.

What does Gilead Sciences Pharmaceuticals Co. do?

Gilead Sciences Pharmaceuticals Co. (吉利德(上海)医药科技有限公司) is a biopharmaceutical company that develops, manufactures, and commercializes innovative prescription medicines for serious and life-threatening diseases. Its therapeutic focus centers on virology (HIV/AIDS and viral hepatitis) and oncology, with the company investing in world-class scientific research and simplified treatment regimens to expand patient access in China. The entity operates as the Chinese regional subsidiary of Gilead Sciences, Inc.

Is Gilead Sciences Pharmaceuticals Co. a public or private company?

Gilead Sciences Pharmaceuticals Co. is a private company. It is classified as corporate owned and is currently operating.

When was Gilead Sciences Pharmaceuticals Co. founded?

Gilead Sciences Pharmaceuticals Co. was founded in 1987. It employs 101 to 250 people.

Where is Gilead Sciences Pharmaceuticals Co. based?

Gilead Sciences Pharmaceuticals Co. is headquartered in Shanghai, China, in the Asia region.

How does Gilead Sciences Pharmaceuticals Co. make money?

One revenue line is on record: pharmaceutical drug sales.

Who are Gilead Sciences Pharmaceuticals Co.'s main competitors?

Broad incumbents on record are Johnson & Johnson Innovative Medicine (China), Novartis (China), AstraZeneca (China), Roche (China) and Pfizer (China). BeiGene is listed as an emerging player. Direct peers are Bristol-Myers Squibb (China), AbbVie (China), GSK (China) and Merck & Co. (MSD China).

Does Gilead Sciences Pharmaceuticals Co. have an API?

No public API is recorded for Gilead Sciences Pharmaceuticals Co..

What industry is Gilead Sciences Pharmaceuticals Co. in?

Gilead Sciences Pharmaceuticals Co.'s product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals, with a secondary code of HLAIAAAB, Specialty Care Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales